|
Malignant neoplasm of breast
|
0.100 |
Biomarker
|
disease |
BEFREE |
We have obtained CTCs-enriched blood fraction from 83 breast cancer patients in which we have tested the expression of epithelial, mesenchymal and general breast cancer CTCs markers (<i>MGB1/HER2/CK19/CDH1/CDH2/VIM/PLS3</i>), cancer stem cell markers (<i>CD44</i>, <i>NANOG</i>, <i>ALDH1</i>, <i>OCT-4</i>, <i>CD133</i>) and cluster formation gene (plakoglobin).
|
30634453 |
2019 |
|
Malignant neoplasm of breast
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Mammaglobin-A (MamA) is overexpressed in 40-80% of all human breast cancers.
|
31091800 |
2019 |
|
Malignant neoplasm of breast
|
0.100 |
Biomarker
|
disease |
BEFREE |
However, no significant cytotoxicity was observed under similar conditions in HLA-A2<sup>+</sup>/Mam-A<sup>-</sup> MCF-7 and MDA-MB-231 breast cancer cell lines.
|
31807192 |
2019 |
|
Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
However, no significant cytotoxicity was observed under similar conditions in HLA-A2<sup>+</sup>/Mam-A<sup>-</sup> MCF-7 and MDA-MB-231 breast cancer cell lines.
|
31807192 |
2019 |
|
Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
We have obtained CTCs-enriched blood fraction from 83 breast cancer patients in which we have tested the expression of epithelial, mesenchymal and general breast cancer CTCs markers (<i>MGB1/HER2/CK19/CDH1/CDH2/VIM/PLS3</i>), cancer stem cell markers (<i>CD44</i>, <i>NANOG</i>, <i>ALDH1</i>, <i>OCT-4</i>, <i>CD133</i>) and cluster formation gene (plakoglobin).
|
30634453 |
2019 |
|
Mammary Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
In this study, VEGFR3 and Ki67 expression but not mammaglobin-A correlated with breast tumour pathology.
|
31263371 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
However, the results revealed that plasma mammaglobin A was not significantly associated with tumor size (OR=1.29; 95% CI=0.46-3.66; <i>P</i>=0.63), tumor differentiation (OR=0.99; 95% CI=0.63-1.57; <i>P</i>=0.97), menopausal status (OR=0.75; 95% CI=0.48-1.18; <i>P</i>=0.22), estrogen receptor status (OR=0.78; 95% CI=0.44-1.36; <i>P</i>=0.38), progesterone receptor status (OR=0.76; 95% CI=0.57-1.02; <i>P</i>=0.07), or human epidermal growth factor receptor 2 status (OR=1.12; 95% CI=0.78-1.59; <i>P</i>=0.54).
|
29881297 |
2018 |
|
Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
In conclusion, the results demonstrate that positive plasma mammaglobin A expression might serve as a biomarker of poor prognosis for breast carcinoma patients.
|
29881297 |
2018 |
|
Malignant neoplasm of breast
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Mammaglobin B (MGB2) and mammaglobin A (MGB1) are proteins expressed in metastatic breast cancers.
|
29101327 |
2017 |
|
Malignant neoplasm of breast
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Interestingly, we also observed that expression of MGB1 confers breast cancer cell sensitivity to anticancer drug-induced apoptosis.
|
26207726 |
2016 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Together, our results support a role for MGB1 in tumor malignancy in exchange for chemosensitivity.
|
26207726 |
2016 |
|
Breast Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Interestingly, we also observed that expression of MGB1 confers breast cancer cell sensitivity to anticancer drug-induced apoptosis.
|
26207726 |
2016 |
|
Malignant neoplasm of breast
|
0.100 |
Biomarker
|
disease |
BEFREE |
HLA-A2(+)/MAM-A(+) breast cancer patients have an increased prevalence of CD8 T cells specific for these novel MAM-A epitopes, and vaccination with a MAM-A DNA vaccine significantly increases the number of these CD8 T cells.
|
25212176 |
2014 |
|
Malignant neoplasm of breast
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Additional studies are required to define the potential of the MAM-A DNA vaccine for breast cancer prevention and/or therapy.
|
25451106 |
2014 |
|
Malignant neoplasm of breast
|
0.100 |
Biomarker
|
disease |
BEFREE |
In addition, mammaglobin A is currently under inves tigation as a potential therapeutic target for immune therapies that target breast cancer.
|
24938021 |
2014 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Overexpression of MGB1 positively correlated with the FIGO stage, the tumor grade and the mitotic index suggesting a patho-physiological role of the protein.
|
24603286 |
2014 |
|
Breast Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Additional studies are required to define the potential of the MAM-A DNA vaccine for breast cancer prevention and/or therapy.
|
25451106 |
2014 |
|
Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
HLA-A2(+)/MAM-A(+) breast cancer patients have an increased prevalence of CD8 T cells specific for these novel MAM-A epitopes, and vaccination with a MAM-A DNA vaccine significantly increases the number of these CD8 T cells.
|
25212176 |
2014 |
|
Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
In addition, mammaglobin A is currently under inves tigation as a potential therapeutic target for immune therapies that target breast cancer.
|
24938021 |
2014 |
|
Malignant neoplasm of breast
|
0.100 |
Biomarker
|
disease |
BEFREE |
In addition, Ad-MGBA-infected DC-stimulated CD8(+) CTLs showed a high level of IFNγ secretion when stimulated with HLA-A33(+)/MGBA(+) breast cancer MDA-MB-415 cells, but not when stimulated with HLA-A33(-)/MGBA(+) HBL-100 and HLA-A33(-)/MGBA(-)MDA-MB-231 cells.
|
23650543 |
2013 |
|
Malignant neoplasm of breast
|
0.100 |
Biomarker
|
disease |
BEFREE |
In this article, we present our results on a phase I clinical trial of a Mam-A cDNA vaccination in breast cancer patients with stage-IV metastatic disease, including the impact of vaccination on the expression of the inducible co-stimulator molecule (ICOS) on CD4 T cells.
|
22678162 |
2013 |
|
Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
In this article, we present our results on a phase I clinical trial of a Mam-A cDNA vaccination in breast cancer patients with stage-IV metastatic disease, including the impact of vaccination on the expression of the inducible co-stimulator molecule (ICOS) on CD4 T cells.
|
22678162 |
2013 |
|
Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
In addition, Ad-MGBA-infected DC-stimulated CD8(+) CTLs showed a high level of IFNγ secretion when stimulated with HLA-A33(+)/MGBA(+) breast cancer MDA-MB-415 cells, but not when stimulated with HLA-A33(-)/MGBA(+) HBL-100 and HLA-A33(-)/MGBA(-)MDA-MB-231 cells.
|
23650543 |
2013 |
|
Malignant neoplasm of breast
|
0.100 |
Biomarker
|
disease |
BEFREE |
In summary, our results define HLA-A24-restricted, Mam-A-derived, CD8(+) CTL epitopes that can potentially be employed for Mam-A-based breast cancer vaccine therapy to breast cancer patients with HLA-A24 phenotype.
|
22074997 |
2012 |
|
Malignant neoplasm of breast
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The secretoglobin mammaglobin 1 (MGB1) is strongly expressed in breast tumours, and is therefore used to detect breast cancer metastases, although it has also been detected in other tissues.
|
22994369 |
2012 |